CNTB Connect Biopharma Holdings Ltd
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835268 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY382.0%
TTM net income YoY-37.9%
TTM EPS YoY-28.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,879.9%
Net margin-1,849.7%
FCF margin-1,504.2%
EBITDA margin-1,861.7%
Returns
ROE-201.5%
ROA-142.8%
ROIC (approx.)-834.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets56.6%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · USD | FY20222022-12-31 · USD | FY20212021-12-31 · CNY |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $64,000 | $26.03M | $0 | — | — |
| R&D expense | $37.80M | $29.26M | $53.00M | $96.63M | 518.02M |
| SG&A expense | $20.34M | $19.23M | $16.05M | — | — |
| Operating income | -$58.07M | -$22.45M | -$69.06M | -$119.32M | -631.44M |
| Interest expense | — | — | $23,000 | $21,000 | 114,000 |
| Pretax income | -$55.28M | -$15.40M | -$61.99M | -$117.79M | -1.31B |
| Income tax | $197,000 | $223,000 | $120,000 | $298,000 | 1.70M |
| Net income | -$55.48M | -$15.63M | -$62.11M | -$118.09M | -1.31B |
| EBITDA | -$57.37M | -$21.79M | -$68.34M | -$118.28M | -627.35M |
| EPS (basic) | -1.00 | -0.28 | -1.13 | -2.15 | -25.00 |
| EPS (diluted) | -1.00 | -0.28 | -1.13 | -2.15 | -25.00 |
| Weighted avg. shares (diluted) | 55.66M | 55.21M | 55.07M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $38.34M | $78.23M | $105.66M | $78.95M | 1.71B |
| Short-term investments | $6.00M | $15.48M | $12.64M | — | — |
| Receivables | $13,000 | $789,000 | $0 | — | — |
| Current assets | $50.93M | $96.96M | $122.55M | $155.78M | 1.75B |
| PP&E, net | $3.81M | $4.05M | $4.27M | $4.98M | 59.34M |
| Intangibles | $45,000 | $53,000 | $62,000 | — | — |
| Total assets | $56.08M | $101.28M | $127.38M | $174.01M | 1.86B |
| Current liabilities | $13.61M | $8.46M | $25.29M | $15.62M | 114.67M |
| Total liabilities | $14.10M | $9.12M | $25.88M | $16.52M | 119.83M |
| Shareholders' equity | $41.98M | $92.17M | $101.50M | $158.42M | 1.74B |
| Shares outstanding | 56.44M | 55.35M | 55.10M | 55.04M | 55.08M |
| Cash flow statement | |||||
| Operating cash flow | -$51.21M | -$23.61M | -$47.74M | -$101.52M | -544.93M |
| Capital expenditure | $434,000 | $750,000 | $81,000 | $4.41M | 24.94M |
| Free cash flow | -$51.64M | -$24.36M | -$47.82M | -$105.92M | -569.87M |
| Investing cash flow | $9.82M | -$3.45M | $74.98M | -$86.24M | -34.02M |
| Financing cash flow | $1.09M | $227,000 | $45,000 | -$85,000 | 1.32B |
| Depreciation & amortization | $704,000 | $660,000 | $720,000 | $1.03M | 4.08M |
| Stock-based compensation | $3.73M | $6.73M | $5.40M | $6.91M | 57.86M |
| Share buybacks | — | — | $0 | $0 | 3.67M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.